Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Januar 2018

Planlagt Fastgjort Låst Flyttet Genmab
2.4k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • J Offline
    J Offline
    JKY_VH
    wrote on sidst redigeret af
    #1191

    😄 Mcj

    1 Reply Last reply
    0
    • G Offline
      G Offline
      GeorgeBest
      wrote on sidst redigeret af
      #1192

      Indtægter fra 4-5 linie behandlinger kan ikke refærdiggøre det. Det same med Gilead der købte Kite for 12 mia USD...

      1 Reply Last reply
      0
      • nohopeN Offline
        nohopeN Offline
        nohope
        wrote on sidst redigeret af
        #1193

        De må se mere I det end 4-5 linie.

        1 Reply Last reply
        0
        • S Offline
          S Offline
          Sukkeralf
          wrote on sidst redigeret af
          #1194

          Det kunne være man skulle prøve at læse lidt om, hvad CAR-T selskaber selv mener det kan bruges til - og analytikere der følgeer disse selskaber

          1 Reply Last reply
          0
          • M Offline
            M Offline
            mobbyduck1
            wrote on sidst redigeret af
            #1195

            JUNO er oppe med 53% i premarket og Bluebird oppe med 8%

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #1196

              a bit more on NICE from MyelomaUK https://www.myeloma.org.uk/news/daratumumab-approved-for-use-on-the-nhs-in-england-and-wales/

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Sukkeralf
                wrote on sidst redigeret af
                #1197

                Indeed, Celgene made it a point at ASH to emphasise the speed at which the company and bluebird will be moving bb2121 forward. A pivotal trial (KarMMa) in late-stage patients will treat an initial patient this month, and the partners plan to start a Phase III trial next year in the third-line setting while simultaneously evaluating the product even further upstream, with a goal of moving into newly diagnosed patients

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #1198

                  should still bring a minumum of €35mn in revenue
                  in the UK this year, no?

                  1 Reply Last reply
                  0
                  • BulderB Offline
                    BulderB Offline
                    Bulder
                    wrote on sidst redigeret af
                    #1199

                    mærkeligt at det er kun 4. linje og ikke 4. linje eller senere.

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #1200

                      yes... but it is correct according to p10 here https://www.england.nhs.uk/wp-content/uploads/2018/01/national-cdf-list-v1.59.pdf

                      1 Reply Last reply
                      0
                      • M Offline
                        M Offline
                        Mcjean
                        wrote on sidst redigeret af
                        #1201

                        Maybe more than 35mn E L. If the first have open for treatment, maybe some patient can apply but i really dont know but im sure the analytics have to rise the estimate, maybe to 2.3 - 2.7?

                        1 Reply Last reply
                        0
                        • M Offline
                          M Offline
                          Mcjean
                          wrote on sidst redigeret af
                          #1202

                          which will happen after 4q and that should result in higher rate, around 2000 i think:-)

                          1 Reply Last reply
                          0
                          • BulderB Offline
                            BulderB Offline
                            Bulder
                            wrote on sidst redigeret af
                            #1203

                            Lyder som chikane: "Note: The use of daratumumab will be audited to confirm it is being used in
                            accordance with these treatment criteria (particularly in respect of lines of therapy)
                            and non-compliant use will be monitored and followed-up."

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #1204

                              funny how that works, whatever calculation you use , we end up at 2000 😄

                              1 Reply Last reply
                              0
                              • laerlingenL Offline
                                laerlingenL Offline
                                laerlingen
                                wrote on sidst redigeret af
                                #1205

                                super dårlig til TA, men kan man betegne udviklingen i GEN som "cup a
                                nd handle"?

                                1 Reply Last reply
                                0
                                • M Offline
                                  M Offline
                                  Mcjean
                                  wrote on sidst redigeret af
                                  #1206

                                  Yep the calulator always end up at 2000, but only this year, next year its gonna be wild:-)

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #1207

                                    MDs possibly have an easier choice now Bulder; after 3 lines they HAVE to choose Dara, otherwise the option is gone. If it doesn't work they can still try something else

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #1208

                                      @ laerlingen , I would personally think the handle is a bit small compared to the cup, but it is very subjective...

                                      1 Reply Last reply
                                      0
                                      • R Offline
                                        R Offline
                                        rex_pacis
                                        wrote on sidst redigeret af
                                        #1209

                                        @laerlingen jeg mener det ikke, den er for kort og ujævn

                                        1 Reply Last reply
                                        0
                                        • laerlingenL Offline
                                          laerlingenL Offline
                                          laerlingen
                                          wrote on sidst redigeret af
                                          #1210

                                          øv øv..men tak 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger